In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed at $7.18 in the last session, up 1.13% from day before closing price of $7.1. In other words, the price has increased by $1.13 from its previous closing price. On the day, 1.48 million shares were traded. BCRX stock price reached its highest trading level at $7.225 during the session, while it also had its lowest trading level at $7.0601.
Ratios:
We take a closer look at BCRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.87.
On October 01, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8. On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 25 ’25 when Helen M Thackray bought 48,229 shares for $6.80 per share.
Helen Thackray bought 43,275 shares of BCRX for $307,685 on Nov 21 ’25. On Nov 13 ’25, another insider, SANDERS MACHELLE, who serves as the Director of the company, sold 9,600 shares for $7.14 each. As a result, the insider received 68,544 and left with 30,642 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1511700352 and an Enterprise Value of 1981936384. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52. Its current Enterprise Value per Revenue stands at 3.304 whereas that against EBITDA is 24.642.
Stock Price History:
The Beta on a monthly basis for BCRX is 0.91, which has changed by -0.027100265 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is 0.27%, while the 200-Day Moving Average is calculated to be -13.91%.
Shares Statistics:
According to the various share statistics, BCRX traded on average about 4.66M shares per day over the past 3-months and 3552410 shares per day over the past 10 days. A total of 210.52M shares are outstanding, with a floating share count of 194.98M. Insiders hold about 7.39% of the company’s shares, while institutions hold 95.41% stake in the company. Shares short for BCRX as of 1763078400 were 36461313 with a Short Ratio of 7.82, compared to 1760486400 on 30773187. Therefore, it implies a Short% of Shares Outstanding of 36461313 and a Short% of Float of 17.379998999999998.
Earnings Estimates
The market rating for Biocryst Pharmaceuticals Inc (BCRX) is a result of the insights provided by 4.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.12, with high estimates of $0.13 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.47 and $0.09 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is $0.29, with 4.0 analysts recommending between $0.7 and -$0.04.
Revenue Estimates
According to 9 analysts, . The current quarter’s revenue is expected to be $151.33M. It ranges from a high estimate of $156.03M to a low estimate of $145.14M. As of . The current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $131.53MFor the next quarter, 9 analysts are estimating revenue of $156.33M. There is a high estimate of $160.58M for the next quarter, whereas the lowest estimate is $151M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $624.31M, while the lowest revenue estimate was $613.1M, resulting in an average revenue estimate of $619.56M. In the same quarter a year ago, actual revenue was $450.71MBased on 10 analysts’ estimates, the company’s revenue will be $665.48M in the next fiscal year. The high estimate is $691.44M and the low estimate is $608M.
